Novartis stock holds as Deutsche Bank keeps Neutral
Published on 09/18/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock (ISIN CH0012005267) held near 116.36 CHF on September 18, 2026, after Deutsche Bank kept its Neutral rating and 120 CHF target. The Swiss drugmaker still had 5% to 6% annual sales growth guidance through 2030 in market commentary published on September 18, 2026.
Target stays at 120 CHF
According to finanzen.ch on September 18, 2026, Deutsche Bank Research kept Novartis at Hold with a 120 CHF price target. The same report put the stock at 116.52 CHF, which leaves only 3.13 percent to the target.
MarketScreener's morning snapshot for September 18, 2026 showed Novartis at 116.50 CHF on Cboe Europe, up 0.41 percent, with a 5-day gain of 3.87 percent and a 1-month gain of 6.19 percent. The average target in that snapshot was 152.93 USD, while the last close was 140.74 USD in the US line.
Growth and pipeline
As Yahoo Finance reported on September 18, 2026, Novartis management reaffirmed full-year financial guidance and kept its target for 5% to 6% compound annual sales growth from 2025 through 2030. The same report said the company had also reported successful late-stage results for remibrutinib in multiple sclerosis.
For investors, the contrast is clear: the share price sits close to 116 CHF, while the long-term sales target still points to 5% to 6 percent growth through 2030. That gap is what the market is weighing against recent clinical setbacks and pipeline progress.
Stock near 116 CHF
Novartis stock traded at 116.52 CHF in Zurich on September 18, 2026, up 0.26 percent on the session. In the same snapshot, the gap to Deutsche Bank's 120 CHF target was 2.99 percent.
Novartis stock facts
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of September 18, 2026): 116.52 CHF
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
